Publication | Closed Access

Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma

UrologySurgical OncologyGenitourinary CancerMedicineImmune Checkpoint InhibitorCancer TreatmentCost-effective Second-line TreatmentOncologyRadiation Oncology